文献速递细胞病理与分子病理神经与头颈病理

非浸润性滤泡性甲状腺肿瘤伴乳头状核特征(NIFTP)的分子检测表现

Young Investigator Challenge: Molecular testing in noninvasive follicular thyroid neoplasm with papillary-like nuclear features.
PubMed 文献 · Cancer Cytopathol · 2016-11-28

4个NIFTP行Afirma基因表达分类器(GEC)检测均判为「可疑」,4个行UPMC ThyroSeq V2检测均检出RAS突变(NRAS、KRAS)。结论提示严格标准下NIFTP罕见,现有分子检测在NIFTP中均显示异常。

要点

  • Afirma GEC在NIFTP中均判为「可疑」,细胞学均为Bethesda III类。
  • UPMC ThyroSeq V2在NIFTP中均检出RAS突变(NRAS或KRAS)。

核心结论

  • 严格标准定义的NIFTP为罕见肿瘤。
  • Afirma GEC与UPMC靶向突变panel在NIFTP中均显示异常。
  • NIFTP的分子与临床特征仍需进一步独立研究。

研究设计与样本

  • 回顾性研究,2012年6月至2016年6月共302个结节送检分子检测。
  • 8个结节符合NIFTP标准,其中4个行Afirma GEC检测、4个行UPMC ThyroSeq V2检测。

主要发现

  • 4个NIFTP行Afirma GEC检测均判为「可疑」。
  • 4个NIFTP行UPMC ThyroSeq V2检测均检出RAS突变(NRAS、KRAS)。
  • 细胞学诊断均为Bethesda III类(3例AUS、1例FLUS),另1例为IV类可疑滤泡性肿瘤。
  • 1例NIFTP患者淋巴结发现转移癌;1例6 cm肿瘤共存NRAS与TERT突变。

关键数值与推荐

  • Afirma GEC在4个NIFTP中均判为「可疑」。
  • UPMC ThyroSeq V2在4个NIFTP中均检出RAS突变(NRAS、KRAS)。
  • 细胞学Bethesda III类中3例为AUS、1例为FLUS,另1例为IV类。

临床怎么用

  • 对细胞学不确定的甲状腺结节,分子检测结果需结合NIFTP可能解读。
  • GEC「可疑」或RAS突变阳性不一定排除NIFTP,术后需严格病理复核。

局限性

  • NIFTP样本量小(8例),分子检测亚组各仅4例。
  • 为单中心回顾性研究,需独立研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Molecular testing provides an important ancillary study for thyroid nodules with indeterminate cytology. The nomenclature shift to "noninvasive follicular thyroid neoplasm with papillary-like nuclear features" (NIFTP) will impact the performance of molecular tests. For the current study, the authors reviewed the performance of the Afirma gene-expression classifier (GEC) and the University of Pittsburgh Medical Center (UPMC) targeted mutation panel tests in thyroid nodules that were subsequently diagnosed as NIFTP on surgical resection. METHODS: In total, 302 nodules were sent for molecular testing between June 2012 and June 2016. These cases were retrospectively reviewed to identify patients who underwent subsequent surgical resection and were diagnosed with follicular variant of papillary thyroid carcinoma (FVPTC). Twenty-five nodules that were diagnosed as FVPTC met the initial inclusion criteria. These cases were reviewed using strict criteria to identify NIFTP. RESULTS: Eight cases met criteria for NIFTP, and 4 NIFTPs underwent Afirma testing. Cytology diagnoses were all Bethesda category III, with 3 diagnosed as atypia of undetermined significance (AUS) and 1 diagnosed as follicular lesion of undetermined significance (FLUS). All of these nodules were identified as "suspicious" using GEC. Four NIFTPs underwent testing at UPMC, all using ThyroSeq V2. The cytology diagnoses for these nodules also were category III, with the exception of 1 nodule that was category IV, suspicious for follicular neoplasm. All NIFTPs were positive for mutations, all of which were RAS mutations (NRAS, KRAS). One patient who had a nodule classified as NIFTP had metastatic carcinoma identified in a lymph node. Another who had a 6-cm tumor had coexisting NRAS and TERT mutations. CONCLUSIONS: The current results indicate that NIFTP is a rare tumor if defined by strict criteria, that both the GEC and UPMC methods indicate abnormalities in NIFTP, and further independent study will be needed to better characterize the molecular and clinical characteristics of NIFTP. Cancer Cytopathol 2016;124:893-900. © 2016 American Cancer Society.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Jiang XS, Harrison GP, Datto MB, et al. Young Investigator Challenge: Molecular testing in noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Cancer Cytopathol. 2016. PMID: 27893191. doi:10.1002/cncy.21802

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。